G6PD杂合子女性接受伯氨喹治疗间日疟时的溶血:根治性治愈方案试验中的巢式队列
在比较间日疟不同治疗方案的随机临床试验中嵌套队列研究,纳入标准NADPH荧光斑点试验结果正常的女性,比较G6PD野生型和G6PD杂合子女性的溶血模式。G6PD杂合子接受高剂量(7天)伯氨喹方案时,临床显著溶血比例和血细胞比容下降幅度均大于标准高剂量(14天)方案。
要点
- G6PD杂合子女性接受7天伯氨喹方案时,临床显著溶血比例为9/17(53%),高于14天方案的2/16(13%),p=0.022。
- 杂合子中7天方案平均血细胞比容下降-20.4%(95%CI -26.0%至-14.8%),14天方案为-13.1%(95%CI -17.6%至-8.6%)。
- 野生型参与者两种剂量下血细胞比容下降均临床不显著且相似。
核心结论
- 较高每日剂量的伯氨喹可能在表型正常的G6PD杂合子女性中引起临床显著溶血。
研究设计与样本
- 在比较间日疟不同治疗方案的随机临床试验中嵌套的队列研究。
- 2012年2月21日至2014年7月4日纳入241名女性参与者,其中34名为G6PD Mahidol变异杂合子。
- 标准NADPH荧光斑点试验结果正常(≳30%-40%正常G6PD活性)的患者随机接受3天氯喹或双氢青蒿素-哌喹联合伯氨喹,伯氨喹为标准高剂量0.5 mg碱基/kg/天×14天或更高剂量1 mg碱基/kg/天×7天。
主要发现
- G6PD杂合子接受7天伯氨喹方案者达到临床显著溶血阈值(血细胞比容相对下降>25%)的比例为9/17(53%),高于14天方案的2/16(13%),p=0.022。
- 杂合子中7天方案平均血细胞比容下降-20.4%(95%CI -26.0%至-14.8%)(第5天达最低点),14天方案为-13.1%(95%CI -17.6%至-8.6%)(第6天达最低点)。
- 两名接受7天伯氨喹方案的杂合子需要输血。
- 野生型参与者中,两种剂量平均血细胞比容下降分别为-5.8%(95%CI -7.2%至-4.4%)(第3天达最低点)和-5.5%(95%CI -7.4%至-3.7%)(第4天达最低点),临床不显著且相似。
局限性
- 该巢式队列研究的主要局限性在于试验的主要目的是评估疗效而非与G6PD基因型相关的溶血,且杂合子组样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD heterozygous females, because of individual variation in the pattern of X-chromosome inactivation (Lyonisation) in erythroid cells, may have low G6PD activity in the majority of their erythrocytes, yet are usually reported as G6PD "normal" by current phenotypic screening tests. Their haemolytic risk when treated with 8-aminoquinolines has not been well characterized. METHODS AND FINDINGS: In a cohort study nested within a randomised clinical trial that compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH fluorescent spot test result (≳30%-40% of normal G6PD activity) were randomised to receive 3 d of chloroquine or dihydroartemisinin-piperaquine in combination with primaquine, either the standard high dose of 0.5 mg base/kg/day for 14 d or a higher dose of 1 mg base/kg/d for 7 d. Patterns of haemolysis were compared between G6PD wild-type and G6PD heterozygous female participants. Between 21 February 2012 and 04 July 2014, 241 female participants were enrolled, of whom 34 were heterozygous for the G6PD Mahidol variant. Haemolysis was substantially greater and a larger proportion of participants reached the threshold of clinically significant haemolysis (fractional haematocrit reduction >25%) in G6PD heterozygotes taking the higher (7 d) primaquine dose (9/17 [53%]) compared with G6PD heterozygotes taking the standard high (14 d) dose (2/16 [13%]; p = 0.022). In heterozygotes, the mean fractional haematocrit reductions were correspondingly greater with the higher primaquine dose (7-d regimen): -20.4% (95% CI -26.0% to -14.8%) (nadir on day 5) compared with the standard high (14 d) dose: -13.1% (95% CI -17.6% to -8.6%) (nadir day 6). Two heterozygotes taking the higher (7 d) primaquine dose required blood transfusion. In wild-type participants, mean haematocrit reductions were clinically insignificant and similar with both doses: -5.8 (95% CI -7.2% to -4.4%) (nadir day 3) compared with -5.5% (95% CI -7.4% to -3.7%) (nadir day 4), respectively. Limitations to this nested cohort study are that the primary objective of the trial was designed to measure efficacy and not haemolysis in relation to G6PD genotype and that the heterozygote groups were small. CONCLUSION: Higher daily doses of primaquine have the potential to cause clinically significant haemolysis in G6PD heterozygous females who are reported as phenotypically normal with current point of care tests. TRIAL REGISTRATION: ClinicalTrials.gov NCT01640574.
引用
- Chu CS, Bancone G, Moore KA, et al. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Med. 2017. PMID: 28170391. doi:10.1371/journal.pmed.1002224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。